2026 Nobel Prize in Chemistry Awarded to "Left and Right Hands": Why the Same Molecule Has Vastly Different Drug Efficacy

Place your left hand over your right hand with both palms facing down, and you will find that your thumbs are always on opposite sides—the left and right hands are mirror images of each other, yet cannot be superimposable. The same is true for drug molecules: the "left-handed" and "right-handed" versions of the same molecule can have vastly different efficacy.This year's Nobel Prize in Chemistry was awarded precisely for this century-old puzzle regarding "handedness".

Image source: Reuters

On October 7, 2026, the Royal Swedish Academy of Sciences announced that the Nobel Prize in Chemistry for this year was awarded to two chemists: 95-year-old French chemist Henri B. Kagan and 76-year-old Japanese chemist Kenso Soai. The citation sounds quite academic: for the discovery of non-linear effects and autocatalysis in asymmetric organic synthesis.

Translated into plain language: they explained how chemical reactions "choose only one hand." And this very phenomenon happens to be the theoretical foundation of quality control for modern chiral drugs.

01

THE PRIZE

Nobel Prize at a Glance: Two Names, One Century-Old Puzzle

Award Information

Laureates: Henri B. Kagan (France, born 1930, Professor Emeritus at Paris-Sud University, now part of Paris-Saclay University); Kenso Soai (Japan, born 1950 in Hiroshima, Professor Emeritus at Tokyo University of Science)

Citation: For the discovery of non-linear effects and autocatalysis in asymmetric organic synthesis

Prize amount: 12 million Swedish kronor, shared equally

Kagan is one of the founders of modern asymmetric catalysis. As early as 1971, he developed the C₂-symmetric chiral diphosphine ligand DIOP, laying an important foundation for subsequent developments in asymmetric hydrogenation and other fields. Kenso Soai is renowned for his research on "asymmetric autocatalysis," and the reaction he discovered was named directly as the "Soai reaction."

Remarkably, Kagan's connection with the Nobel Prize was delayed by a full 25 years. In 2001, he won the Wolf Prize in Chemistry alongside Ryoji Noyori and K. Barry Sharpless; however, the Nobel Prize in Chemistry that same year was awarded only to William S. Knowles, Ryoji Noyori, and K. Barry Sharpless, leaving Kagan out—a decision that sparked widespread debate in academia at the time. Twenty-five years later, this medal has finally found its way to him.

Image source: Nobel Prize Official Website

02

CHIRALITY

What is Chirality? Why Does Life "Use Only One Hand"?

Returning to the hands mentioned at the beginning: many molecules are the same, existing in "left-handed" and "right-handed" forms. Chemists refer to this property as chirality, and call this pair of mirror-image molecules enantiomers.

Life has an almost obsessive preference for "handedness": it uses only one of them.

The amino acids that make up the proteins in our bodies are almost entirely "left-handed" (designated as L-form in chemistry); the sugars that constitute DNA and RNA are almost entirely "right-handed" (D-form). This phenomenon in living systems of "recognizing only one hand" is called homochirality.

In the laboratory, however, the situation is quite the opposite. Without deliberate guidance, ordinary chemical reactions show no bias whatsoever: left-handed and right-handed molecules always form in equal amounts (50:50). Such a mixture is called a racemate.

On one side is life's one-sided preference, and on the other is chemical reactions' 50:50 split. The question then arises: at the origin of life, with no external help, how did this bias emerge spontaneously?

As early as 1953, British physicist F. C. Frank proposed theoretically that if a reaction product could catalyze its own formation while suppressing its mirror image, a minuscule initial bias could be gradually amplified. However, for decades, this remained purely on paper.

03

THE SCIENCE

What Exactly Did They Get Right?

It was Kagan and Kenso Soai who brought this concept off the paper. One after the other, each completed a critical step.

Step 1: Kagan discovered the "non-linear effect" (1986)

Conventional understanding held that the enantiomeric purity of the product (enantiomeric excess, ee) should be directly proportional to the purity of the chiral catalyst used: a 30% reduction in catalyst purity would result in a 30% reduction in product purity. Kagan, however, discovered that this 1:1 relationship does not always hold. In certain reactions, even if the catalyst itself is not entirely enantiopure, the excess of one mirror-image form in the product can far exceed expectations.

The reason lies in the fact that catalyst molecules tend to pair up with each other. Complexes formed by homochiral molecules and those formed by heterochiral molecules possess different catalytic activities, with the latter sometimes being virtually inactive. This is the non-linear effect. For the first time, it demonstrated to chemists that enantioselectivity could be "amplified."

Step 2: Kenso Soai achieved "asymmetric autocatalysis" (1995–2003)

In 1995, Kenso Soai reported a unique class of reactions: the reaction product itself acts as the catalyst and exclusively catalyzes the formation of molecules with the same chirality as itself. Acting like a "photocopier," each round replicates and amplifies chirality. An extremely subtle initial bias, after several rounds of reaction, can be amplified to near enantiomeric purity. In 2003, he ultimately achieved a reaction that produces only one of the two mirror-image forms.

Thus, Frank's theoretical model from half a century earlier was finally validated experimentally. Heiner Linke, Chair of the Nobel Committee for Chemistry, commented that the two laureates provided the answer to a century-old chemical puzzle: how homochirality arises spontaneously. In the official announcement, the Soai reaction was hailed as "one of the most spectacular chemical experiments ever performed."

04

PHARMA

From the Nobel Prize to the Pharmacy: Why Chirality Determines Efficacy

Why was a chemistry problem concerning the origin of life described by the Nobel Committee as being of "decisive significance" to chemists designing drug manufacturing reactions? The answer comes down to a single sentence: Chirality directly impacts drug efficacy and safety.

Receptors and enzymes in the human body are inherently chiral. When two mirror-image drug molecules enter the human body, they may interact with the same target in drastically different ways: one may be active, while the other is weakly active, inactive, or even causes adverse reactions.

The heaviest lesson in pharmaceutical history came from the thalidomide ("Contergan") tragedy in the late 1950s and early 1960s. Marketed as a racemic mixture, the drug caused birth defects in tens of thousands of infants worldwide. Studies suggest that its (S)-enantiomer is linked to teratogenic effects.

Supplementary note: Subsequent research showed that the two enantiomers of thalidomide interconvert in vivo, meaning that administering a single enantiomer alone does not avert the risk; its teratogenic mechanism is far more complex than the simplistic narrative of "one is safe, the other is teratogenic." However, this does not alter the fundamental conclusion: precise understanding and control of chirality represent the baseline of drug safety.

For this reason, an increasing number of chiral drugs are marketed as single enantiomers. For example, the quinolone antibacterial drug levofloxacin is the (S)-enantiomer of racemic ofloxacin, possessing approximately twice the antibacterial activity of ofloxacin; the antiallergic drug dexchlorpheniramine achieves therapeutic efficacy comparable to racemic chlorpheniramine at about half the dose.

This brings a mandatory requirement: when a drug is marketed as a single enantiomer, the "other hand"—that is, the level of enantiomeric impurities—must be strictly controlled. ICH Q6A establishes specific quality control decision trees for chiral active pharmaceutical ingredients and drug products, and pharmacopoeias worldwide generally mandate checks for enantiomeric or optical purity. Because two enantiomers possess virtually identical physical and chemical properties, conventional chromatographic methods cannot separate them, making enantiomeric impurity analysis one of the most technically demanding steps in impurity research.

The Nobel Prize addresses "why life uses only one hand"; process development and analytical chemistry must solve "how to control the other hand."

05

STANDARDS

Controlling the "Other Hand" Requires a Standard Ruler

How exactly can the "other hand" be kept under control?

The most commonly used method is chiral chromatography: utilizing a chiral column or chiral mobile phase to separate the two mirror-image molecules for individual quantification. However, all of this relies on an indispensable prerequisite: there must be an enantiomeric reference standard with a defined structure and reliable purity, used to locate impurity peaks, assess resolution, and validate method accuracy. Without this "standard ruler," even the most sophisticated instruments are helpless.

This is precisely the domain in which Guangzhou CATO Tech Co., Ltd. (CATO) has been deeply engaged for years.

Dual-System Accreditation

CNAS + ANAB RM0030 & AR-2832 Dual ISO 17034

139,900+Reference Standards

Covering method development to regulatory submission

Comprehensive Characterization

HPLC, NMR, MS, etc.

COA accompanied by uncertainty values and original spectra

As a reference material producer accredited under dual ISO 17034 standards by both CNAS and ANAB, CATO can provide chiral impurity and enantiomeric reference standards with well-defined structures and traceable property values, featuring complete COA information to support regulatory filings.

In the area of chiral drug impurity control, CATO has accumulated mature products and extensive expertise. For example:

1.Dexchlorpheniramine: Marketed as a single (S)-enantiomer (dextrorotatory form), the residual levorotatory enantiomer from production must be strictly controlled. CATO provides high-purity enantiomeric reference standards for chiral HPLC method development and quantification, meeting pharmacopoeial enantiomeric purity testing requirements.

2.Ezetimibe: The molecule contains 3 chiral centers, resulting in a total of 8 stereoisomers. CATO provides all 7 stereoisomers other than the target configuration for chiral purity evaluation and individual comparative studies.

3.Levofloxacin: As the (S)-enantiomer of ofloxacin, its (R)-enantiomer (dextrofloxacin) is a key chiral impurity requiring strict control. CATO supplies dextrofloxacin as well as reference standards for the main impurities of this drug substance.

Note: Numbering and abbreviations for stereoisomeric impurities can vary among manufacturers (e.g., "Impurity X", "R-Isomer", etc.), making compounds with multiple chiral centers particularly prone to confusion. When purchasing and comparing standards, it is recommended to rely on CAS numbers and chemical structures.

In-stock catalog reference standards are shipped on the same day. For special stereoisomers and derivatives outside the catalog that are difficult to obtain, custom synthesis services are also available.

∞

EPILOGUE

From "Why" to "How"

Over a century ago, chemists asked: Why does life use only one hand? Today, pharmaceutical professionals ask: How do we strictly control the other hand?

The Nobel Prize answers the former—a romantic inquiry into the origins of life; the industry in which CATO operates answers the latter—a matter directly affecting whether every single dose of medicine safely reaches the hands of patients.From "why" to "how," providing the standard ruler to measure chirality is precisely what we do.

END

Guangzhou CATO Tech Co., Ltd. (CATO) | Comprehensive reference standard solution provider, accredited under dual ISO 17034 (CNAS RM0030 + ANAB AR-2832). For relevant products and technical support, feel free to leave a message via our Official Account background, or visit CATO's official website  www.en.cato-chem.com  to search.